Trimer IgG and neutralising antibody response to COVID-19 mRNA vaccination in individuals with sarcoidosis.
Christen L VagtsYi-Shin ChangChristian AscoliJessica M LeeKai HuangYue HuangRuth A CherianNandini SarupSamantha R WarpechaRussell Edafetanure-IbehMd-Ruhul AminTasmin SultanaMahmood GhassemiNadera J SweissRichard NovakDavid L PerkinsPatricia W FinnPublished in: ERJ open research (2023)
Sarcoidosis subjects exhibit nAb induced by the BNT162b2 mRNA SARS-CoV-2 vaccine at levels comparable to controls that persists at 6 months indicating conferred immunity. Trimer IgG levels are poor predictors of nAb in subjects with sarcoidosis. Studies of further antibody immunoglobulins and subtypes warrant investigation.